Medtronic touts real-world outcomes for MiniMed 670G
The company this week also landed major regulatory wins for its automated insulin dosing device – the MiniMed 670G won an expanded approval in the U.S., extending the product’s use to children under the age of 7. In the European Union, Medtronic won CE Mark clearance for the system.
From its real-world study, the medtech giant reported that users across all age groups had an average ‘Time in Range’ of 70.6%. The system’s SmartGuard Hybrid Closed algorithm boosted ‘Time in Range’ by 41.1% compared to reference data from patients managing their diabetes with multiple daily injections in the STAR3 trial.
“These data are compelling and demonstrate that [multiple daily injection] patients are doing very well on the MiniMed 670G system and are experiencing significant Time in Range improvements,” Dr. Anders Carlson, medical director of the International Diabetes Center said in prepared remarks. “In addition to the clinical benefits, reducing mental burden associated with diabetes management is a key component to improving their overall wellness and this innovative system is a major step towards that goal.”
Importantly, Medtronic noted that a 2,534-patient analysis showed that more than 85% of patients experienced positive outcomes related to energy & mobility, diabetes control, anxiety & worry, social burden and sexual functioning.
“I am pleased to see that the great results we saw in the controlled pivotal trial are mirrored in the commercial use of this therapy and that patients are living full and healthy lives on this system,” Dr. Francine Kaufman, CMO of Medtronic’s diabetes group, added.
NEXT: Insulet reports positive clinical trial results for Omnipod Horizon